Akebia Therapeutics Ownership | Who Owns Akebia Therapeutics?
Akebia Therapeutics Ownership Summary
Akebia Therapeutics is owned by 32.23% institutional investors, 2.20% insiders, and 65.57% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 7.18% of AKBA shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 3.32% of its assets in Akebia Therapeutics shares.
AKBA Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Akebia Therapeutics | 32.23% | 2.20% | 65.57% |
| Sector | Healthcare Stocks | 57.39% | 9.93% | 32.68% |
| Industry | Biotech Stocks | 68.48% | 9.65% | 21.87% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Blackrock funding, inc. /de | 15.10M | 7.18% | $28.69M |
| Blackrock | 11.64M | 5.68% | $11.87M |
| Vanguard group | 10.88M | 5.17% | $20.68M |
| State street | 6.30M | 3.00% | $11.98M |
| Alerce investment management | 5.75M | 2.73% | $10.92M |
| Geode capital management | 4.80M | 2.28% | $9.11M |
| Renaissance | 3.82M | 1.82% | $7.26M |
| Jacobs levy equity management | 2.09M | 1.02% | $2.14M |
| Qube research | 1.19M | 0.57% | $2.26M |
| Connor, clark & lunn investment management | 1.03M | 0.49% | $1.95M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Alerce investment management | 5.75M | 19.23% | $10.92M |
| Exome asset management | 205.96K | 0.29% | $391.32K |
| Diametric capital, lp | 88.11K | 0.11% | $167.42K |
| Orchard capital management | 60.71K | 0.05% | $115.35K |
| Alphamark advisors | 38.46K | 0.03% | $73.00K |
| Wealth effects | 32.00K | 0.02% | $60.80K |
| Eagle wealth strategies | 10.00K | 0.01% | $19.00K |
| Prelude capital management | 93.15K | 0.01% | $176.99K |
| Renaissance | 3.82M | 0.01% | $7.26M |
| Two sigma securities | 40.83K | 0.01% | $77.57K |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Blackrock | 11.64M | 0.00% | 9.10M |
| State street | 6.30M | 0.00% | 2.87M |
| Vanguard group | 10.88M | 0.00% | 813.90K |
| Goldman sachs group | 1.00M | 0.00% | 516.92K |
| Jacobs levy equity management | 2.09M | 0.01% | 457.15K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Acadian asset management | - | - | -4.06M |
| Eam investors | - | - | -428.55K |
| Cubist systematic strategies | - | - | -398.25K |
| Marshall wace, llp | - | - | -247.07K |
| Boothbay fund management | - | - | -240.00K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Exome asset management | 205.96K | 0.29% | 205.96K | $391.32K |
| Rafferty asset management | 179.75K | 0.00% | 179.75K | $341.53M |
| Simplex trading | 128.98K | 0.00% | 128.98K | $245.00K |
| Dimensional fund advisors lp | 125.68K | 0.00% | 125.68K | $238.79K |
| Prelude capital management | 93.15K | 0.01% | 93.15K | $176.99K |
Sold Out
| Holder | Change |
|---|---|
| Capital performance advisors llp | -68.00 |
| Hexagon capital partners | -186.00 |
| Headlands | -208.00 |
| Laurel wealth advisors | -229.00 |
| Redwood wealth management group | -300.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 124 | 4.20% | 67,787,367 | 14.05% | 32 | 4.04% | 70 | 18.64% | 22 | -15.38% |
| Sep 30, 2024 | 118 | 9.26% | 59,390,703 | 5.52% | 28 | 3.74% | 59 | 9.26% | 26 | 8.33% |
| Jun 30, 2024 | 108 | -14.29% | 56,234,084 | -1.41% | 27 | 3.04% | 53 | -27.40% | 24 | - |
| Mar 31, 2024 | 126 | 38.46% | 57,038,634 | 4.20% | 30 | 3.55% | 73 | 97.30% | 24 | 14.29% |
| Dec 31, 2023 | 91 | 13.75% | 54,737,421 | 7.65% | 29 | 3.92% | 37 | 32.14% | 21 | - |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 7.84M | 3.32% | 1.65M |
| Vanguard US Total Market Shares ETF | 5.95M | 2.52% | - |
| iShares Russell 2000 ETF | 5.79M | 2.22% | -50.22K |
| Vanguard Institutional Extnd Mkt Idx Tr | 3.19M | 1.35% | -99.34K |
| SPDR® S&P Biotech ETF | 2.53M | 0.97% | -27.14K |
| Fidelity Small Cap Index | 2.07M | 0.79% | -38.71K |
| Franklin Biotechnology Discv A(acc)USD | 1.60M | 0.68% | 1.60M |
| iShares Russell 2000 Value ETF | 1.77M | 0.68% | - |
| State St Russell Sm/Mid Cp® Indx SL Cl I | 1.25M | 0.53% | -125.40K |
| State St Russell Sm/Mid Cp® Indx NL Cl C | 1.25M | 0.53% | -125.40K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Mar 03, 2025 | Butler John P. | CEO and President | Sell | $84.93K |
| Mar 03, 2025 | Burke Steven Keith | SVP, Chief Medical Officer | Sell | $13.07K |
| Feb 03, 2025 | Butler John P. | CEO and President | Sell | $205.76K |
| Feb 03, 2025 | Butler John P. | CEO and President | Sell | $97.16K |
| Feb 03, 2025 | Burke Steven Keith | SVP, Chief Medical Officer | Sell | $48.87K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q1 | - | 8 |
| 2024 Q2 | - | 2 |
| 2024 Q1 | - | 10 |
| 2023 Q3 | - | 1 |
| 2023 Q2 | - | 4 |
AKBA Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools